Novartis acquires local cardiovascular drugmaker Anthos for $925 million
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.
pharmaphorum6d
Novartis lines up Merck exec to replace R&D leader Jay Bradner
Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...
Business Insider6y
Novartis is betting that AI is the 'next great tool' for finding new, cutting-edge medicines. Here's how the $220 billion drug giant is using it.
As president of the Novartis Institutes for BioMedical Research, or NIBR, Bradner leads the company's drug research and discovery. But, speaking at the World Economic Forum in Davos, Switzerland ...
Harvard Business School7y
China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise
Sato, Vicki, Christoph Jaeker, and Pooja Mehta Solanki. "China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise." Harvard Business School ...
pharmaphorum2d
AI helping us make smarter, faster decisions, says Novartis R&D chief
Then in October the company unveiled a major restructuring of its global R&D organisation, led from its headquarters in Basel, Switzerland and the Novartis Institutes for BioMedical Research (NIBR ...
C&EN28d
Q&A: What Novartis’s biomedical research head sees in AI
One year ago this week, Novartis biomedical research president Fiona Marshall called artificial intelligence a technology with “the potential to transform how we discover new drugs.” ...
Lupus Foundation of America3y
Ronenn Roubenoff, MD
Dr. Roubenoff is Head of Global Translational Medicine for Musculoskeletal Diseases at Novartis Institutes for Biomedical Research. He has done pioneering work on the interactions of nutrition, ...